Tianjing Li

Tianjing Li

Auto-generated profile, based on publicly available information

Tianjing Li

Department of Ophthalmology, University of Colorado Anschutz Medical Campus, Aurora, CO, USA

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 September 2020 in MetaArXiv
Verified
Preprint
Open access
MPMatthew James Page
Matthew James Page
JMJoanne McKenzie
Joanne McKenzie
PBPatrick Bossuyt
Patrick Bossuyt
IBIsabelle Boutron
Isabelle Boutron
THTammy Hoffmann
Tammy Hoffmann
DMDavid Moher
David Moher
Background: The Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) Statement, published in 2009, was designed to help systematic reviewers transparently report why the review was done, what the authors did and what they found. Over the last decade, there have been many advances in systematic review methodology and terminology, which have necessitated an update to the guideline.Objectives: To develop the PRISMA 2020 statement for reporting systematic reviews.Methods: We reviewed 60 documents with reporting guidance for systematic reviews to generate suggested modifications to the PRISMA 2009 statement. We sought feedback on the suggested modifications through an online survey of 110 systematic review methodologists and journal editors. The results of the review and survey were discussed at a 21-member in-person meeting. Following the meeting, drafts of the PRISMA 2020 checklist, abstract checklist, explanation and elaboration and flow diagram were generated and refined iteratively based on feedback from co-authors and a convenience sample of 15 systematic reviewers.Results: In this statement paper, we present the PRISMA 2020 27-item checklist, an expanded checklist that details reporting recommendations for each item, the PRISMA 2020 abstract checklist, and the revised flow diagrams for original and updated reviews. The checklist includes new reporting guidance that reflects advances in methods to identify, select, appraise and synthesise studies. The structure and presentation of the items have been modified to facilitate implementation. The PRISMA 2020 statement replaces the 2009 statement.Conclusions: The PRISMA 2020 statement is intended to facilitate transparent, complete and accurate reporting of systematic reviews. Improved reporting should benefit users of reviews, including guideline developers, policy makers, health care providers, patients and other stakeholders. In order to achieve this, we encourage authors, editors and peer-reviewers to adopt the guideline.

1 December 2022 in JAMA Ophthalmology
Verified
Journal Article
Open access
PDF file
PMPaul McCann
Paul McCann
AAAlison G. Abraham
Alison G. Abraham
AMAdhuna Mukhopadhyay
Adhuna Mukhopadhyay
KPKanella Panagiotopoulou
Kanella Panagiotopoulou
HCHongan Chen
Hongan Chen
TLTianjing Li
Tianjing Li
The Tear Film and Ocular Surface Society (TFOS) Dry Eye Workshop II (DEWS-II) defines dry eye disease (DED) as “a multifactorial disease of the ocular surface characterized by a loss of homeostasis of the tear film, and accompanied by ocular symptoms, in which tear film instability and hyperosmolarity, ocular surface inflammation and damage, and neurosensory abnormalities play etiological roles.”1 Because there is no gold standard diagnostic test for DED,1 we use the term dry eye to describe various presentations of ocular discomfort and visual disturbance caused by tear film abnormalities.

3 November 2021 in Journal of Clinical Epidemiology
Verified
Journal Article
Open access
RQRiaz Qureshi
Riaz Qureshi
EMEvan Mayo-Wilson
Evan Mayo-Wilson
TLTianjing Li
Tianjing Li
Most systematic reviews of interventions focus on potential benefits. Common methods and assumptions that are appropriate for assessing benefits can be inappropriate for harms. This paper provides a primer on researching harms, particularly in systematic reviews. Commentary describing challenges with assessing harm. Investigators should be familiar with various terminologies used to describe, classify, and group harms. Published reports of clinical trials include limited information about harms, so systematic reviewers should not depend on these studies and journal articles to reach conclusions about harms. Visualizations might improve communication of multiple dimensions of harms such as severity, relatedness, and timing. The terminology, classification, detection, collection, and reporting of harms create unique challenges that take time, expertise, and resources to navigate in both primary studies and evidence syntheses. Systematic reviewers might reach incorrect conclusions if they focus on evidence about harms found in published reports of randomized trials of a particular health problem. Systematic reviews could be improved through better identification and reporting of harms in primary studies and through better training and uptake of appropriate methods for synthesizing evidence about harms.

31 January 2024 in BMC Ophthalmology
Verified
Journal Article
Open access
PDF file
HCHongan Chen
Hongan Chen
PMPaul McCann
Paul McCann
TLTiffany Lien
Tiffany Lien
MXMengli Xiao
Mengli Xiao
AAAlison G. Abraham
Alison G. Abraham
TLTianjing Li
Tianjing Li
Background: Dry eye is one of the most common ophthalmic conditions and can significantly impact quality of life. Meibomian gland dysfunction (MGD) is a major cause of evaporative dry eye. We sought to conduct a systematic review and meta-analysis to estimate the prevalence and incidence of dry eye and MGD in Central and South America and to identify factors associated with disease burden. Methods: Data sources Ovid MEDLINE and Embase. Study selection: A search conducted on August 16, 2021, identified studies published between January 1, 2010, and August 16, 2021, with no restrictions regarding participant age or language of publication. Case reports, case series, case–control studies, and interventional studies were excluded. Data extraction and synthesis: The review was based on a protocol registered on PROSPERO (CRD42021256934). Risk of bias was assessed in duplicate using a risk of bias tool designed for the purposes of descriptive epidemiological studies. Data were extracted by one investigator and verified by another for accuracy. Prevalence of dry eye and MGD were grouped based on study participant characteristics. Main outcomes and measures: Prevalence and incidence of dry eye and MGD in Central and South America. Summary estimates from meta-analysis with 95% confidence intervals (CI). Results: Fourteen studies (11,594 total participants) were included. The population prevalence of dry eye was 13% (95% CI, 12%-14%) in Brazil and 41% (95% CI, 39%-44%) in Mexico based on one study each. Meta-analyses suggested that dry eye prevalence was 70% among indoor workers (95% CI, 56%-80%; I2, 82%; 3 studies), 71% among students (95% CI, 65%-77%; I2, 92%; 3 studies), and 83% in general ophthalmology clinics (95% CI, 77%-88%; I2, 88%; 2 studies). MGD prevalence ranged from 23% among indoor workers (95% CI, 16%-31%; 1 study) to 68% in general ophthalmology clinics (95% CI, 62%-72%; 1 study). No studies reported incidence of dry eye or MGD. Conclusions: This systematic review and meta-analysis demonstrated considerable variation in the published prevalence of dry eye and MGD among the general population and subpopulations in Central and South America. Local and subpopulation estimates of dry eye disease burden may be valuable to assist needs assessments and implementation of measures to mitigate the condition.

6 January 2025 in BMJ
Verified
Journal Article
Open access
PDF file
JMJoanne E McKenzie
Joanne E McKenzie
MTMonica Taljaard
Monica Taljaard
KHKarla Hemming
Karla Hemming
SASarah J Arnup
Sarah J Arnup
BGBruno Giraudeau
Bruno Giraudeau
AFAndrew Forbes
Andrew Forbes
This article presents the CONSORT (consolidated standards of reporting trials) extension for cluster randomised crossover trials. A cluster randomised crossover trial involves randomisation of groups of individuals (known as clusters) to different sequences of interventions over time. The design has gained popularity in settings where cluster randomisation is required because it can largely overcome the loss in power due to clustering in parallel cluster trials. However, the design has many methodological complexities, requiring tailored reporting guidance. The guideline was developed using a survey and in-person consensus meeting, informed by a systematic review examining the quality of reporting in cluster randomised crossover trials and relevant CONSORT statements for individual, crossover, cluster, and stepped wedge designs. This article also provides recommended reporting items, along with explanations and examples.

28 October 2020 in Trials
Verified
Journal Article
Open access
PDF file
KHKarla Hemming
Karla Hemming
AKAnna Kearney
Anna Kearney
CGCarrol Gamble
Carrol Gamble
TLTianjing Li
Tianjing Li
PJPeter Jüni
Peter Jüni
MSMatthew R. Sydes
Matthew R. Sydes